Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 275

1.

Type of RNA Packed in VLPs Impacts IgG Class Switching-Implications for an Influenza Vaccine Design.

C Gomes A, Roesti ES, El-Turabi A, Bachmann MF.

Vaccines (Basel). 2019 Jun 4;7(2). pii: E47. doi: 10.3390/vaccines7020047.

2.

Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine.

Mohsen MO, Vogel M, Riether C, Muller J, Salatino S, Ternette N, Gomes AC, Cabral-Miranda G, El-Turabi A, Ruedl C, Kundig TM, Dermime S, Knuth A, Speiser DE, Bachmann MF.

Front Immunol. 2019 May 15;10:1015. doi: 10.3389/fimmu.2019.01015. eCollection 2019.

3.

Correction to: Vaccination with nanoparticles combined with micro-adjuvants protects against cancer.

Mohsen MO, Heath MD, Cabral-Miranda G, Lipp C, Zeltins A, Sande M, Stein JV, Riether C, Roesti E, Zha L, Engeroff P, El-Turabi A, Kundig TM, Vogel M, Skinner MA, Speiser DE, Knuth A, Kramer MF, Bachmann MF.

J Immunother Cancer. 2019 May 23;7(1):137. doi: 10.1186/s40425-019-0616-y.

4.

Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjects.

Thoms F, Jennings GT, Maudrich M, Vogel M, Haas S, Zeltins A, Hofmann-Lehmann R, Riond B, Grossmann J, Hunziker P, Fettelschoss-Gabriel A, Senti G, Kündig TM, Bachmann MF.

J Allergy Clin Immunol. 2019 Apr 17. pii: S0091-6749(19)30349-5. doi: 10.1016/j.jaci.2019.01.050. [Epub ahead of print]

5.

Vaccination with nanoparticles combined with micro-adjuvants protects against cancer.

Mohsen MO, Heath MD, Cabral-Miranda G, Lipp C, Zeltins A, Sande M, Stein JV, Riether C, Roesti E, Zha L, Engeroff P, El-Turabi A, Kundig TM, Vogel M, Skinner MA, Speiser DE, Knuth A, Kramer MF, Bachmann MF.

J Immunother Cancer. 2019 Apr 26;7(1):114. doi: 10.1186/s40425-019-0587-z. Erratum in: J Immunother Cancer. 2019 May 23;7(1):137.

6.

RNA and Toll-Like Receptor 7 License the Generation of Superior Secondary Plasma Cells at Multiple Levels in a B Cell Intrinsic Fashion.

Krueger CC, Thoms F, Keller E, Leoratti FMS, Vogel M, Bachmann MF.

Front Immunol. 2019 Apr 5;10:736. doi: 10.3389/fimmu.2019.00736. eCollection 2019.

7.

Immunogenicity and Immunodominance in Antibody Responses.

Vogel M, Bachmann MF.

Curr Top Microbiol Immunol. 2019 Mar 28. doi: 10.1007/82_2019_160. [Epub ahead of print]

PMID:
30919087
8.

Active immunisation targeting nerve growth factor attenuates chronic pain behaviour in murine osteoarthritis.

von Loga IS, El-Turabi A, Jostins L, Miotla-Zarebska J, Mackay-Alderson J, Zeltins A, Parisi I, Bachmann MF, Vincent TL.

Ann Rheum Dis. 2019 May;78(5):672-675. doi: 10.1136/annrheumdis-2018-214489. Epub 2019 Mar 12.

9.

The thioredoxin-1 and glutathione/glutaredoxin-1 systems redundantly fuel murine B-cell development and responses.

Muri J, Thut H, Heer S, Krueger CC, Bornkamm GW, Bachmann MF, Kopf M.

Eur J Immunol. 2019 May;49(5):709-723. doi: 10.1002/eji.201848044. Epub 2019 Mar 1.

PMID:
30802940
10.

A vaccine against Alzheimer`s disease: anything left but faith?

Bachmann MF, Jennings GT, Vogel M.

Expert Opin Biol Ther. 2019 Jan;19(1):73-78. doi: 10.1080/14712598.2019.1554646. Epub 2018 Dec 17. Review.

PMID:
30526133
11.

The 5th virus-like particle and nano-particle vaccines (VLPNPV) conference.

Engeroff P, Bachmann MF.

Expert Rev Vaccines. 2019 Jan;18(1):1-3. doi: 10.1080/14760584.2019.1557522. Epub 2018 Dec 13.

PMID:
30526126
12.

The Prospects of an Active Vaccine Against Asthma Targeting IL-5.

Bachmann MF, El-Turabi A, Fettelschoss-Gabriel A, Vogel M.

Front Microbiol. 2018 Oct 24;9:2522. doi: 10.3389/fmicb.2018.02522. eCollection 2018. Review.

13.

Active vaccination against interleukin-5 as long-term treatment for insect-bite hypersensitivity in horses.

Fettelschoss-Gabriel A, Fettelschoss V, Olomski F, Birkmann K, Thoms F, Bühler M, Kummer M, Zeltins A, Kündig TM, Bachmann MF.

Allergy. 2019 Mar;74(3):572-582. doi: 10.1111/all.13659. Epub 2018 Nov 25.

14.

Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System.

Mohsen MO, Gomes AC, Vogel M, Bachmann MF.

Vaccines (Basel). 2018 Jul 2;6(3). pii: E37. doi: 10.3390/vaccines6030037. Review.

15.

Biosensor-based selective detection of Zika virus specific antibodies in infected individuals.

Cabral-Miranda G, Cardoso AR, Ferreira LCS, Sales MGF, Bachmann MF.

Biosens Bioelectron. 2018 Aug 15;113:101-107. doi: 10.1016/j.bios.2018.04.058. Epub 2018 May 1.

PMID:
29751200
16.

Treating insect-bite hypersensitivity in horses with active vaccination against IL-5.

Fettelschoss-Gabriel A, Fettelschoss V, Thoms F, Giese C, Daniel M, Olomski F, Kamarachev J, Birkmann K, Bühler M, Kummer M, Zeltins A, Marti E, Kündig TM, Bachmann MF.

J Allergy Clin Immunol. 2018 Oct;142(4):1194-1205.e3. doi: 10.1016/j.jaci.2018.01.041. Epub 2018 Apr 4.

17.

Vaccination against IL-31 for the treatment of atopic dermatitis in dogs.

Bachmann MF, Zeltins A, Kalnins G, Balke I, Fischer N, Rostaher A, Tars K, Favrot C.

J Allergy Clin Immunol. 2018 Jul;142(1):279-281.e1. doi: 10.1016/j.jaci.2017.12.994. Epub 2018 Apr 4. No abstract available.

PMID:
29627081
18.

An unexpected protective role of low-affinity allergen-specific IgG through the inhibitory receptor FcγRIIb.

Zha L, Leoratti FMS, He L, Mohsen MO, Cragg M, Storni F, Vogel M, Bachmann MF.

J Allergy Clin Immunol. 2018 Nov;142(5):1529-1536.e6. doi: 10.1016/j.jaci.2017.09.054. Epub 2018 Jan 31.

PMID:
29391255
19.

Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer's and cat allergy.

Zeltins A, West J, Zabel F, El Turabi A, Balke I, Haas S, Maudrich M, Storni F, Engeroff P, Jennings GT, Kotecha A, Stuart DI, Foerster J, Bachmann MF.

NPJ Vaccines. 2017 Oct 23;2:30. doi: 10.1038/s41541-017-0030-8. eCollection 2017.

20.

A novel recycling mechanism of native IgE-antigen complexes in human B cells facilitates transfer of antigen to dendritic cells for antigen presentation.

Engeroff P, Fellmann M, Yerly D, Bachmann MF, Vogel M.

J Allergy Clin Immunol. 2018 Aug;142(2):557-568.e6. doi: 10.1016/j.jaci.2017.09.024. Epub 2017 Oct 23.

PMID:
29074459
21.

Microcrystalline Tyrosine (MCT®): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria.

Cabral-Miranda G, Heath MD, Gomes AC, Mohsen MO, Montoya-Diaz E, Salman AM, Atcheson E, Skinner MA, Kramer MF, Reyes-Sandoval A, Bachmann MF.

Vaccines (Basel). 2017 Sep 27;5(4). pii: E32. doi: 10.3390/vaccines5040032.

22.

Major findings and recent advances in virus-like particle (VLP)-based vaccines.

Mohsen MO, Zha L, Cabral-Miranda G, Bachmann MF.

Semin Immunol. 2017 Dec;34:123-132. doi: 10.1016/j.smim.2017.08.014. Epub 2017 Sep 5. Review.

PMID:
28887001
23.

Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles.

Doucet M, El-Turabi A, Zabel F, Hunn BHM, Bengoa-Vergniory N, Cioroch M, Ramm M, Smith AM, Gomes AC, Cabral de Miranda G, Wade-Martins R, Bachmann MF.

PLoS One. 2017 Aug 10;12(8):e0181844. doi: 10.1371/journal.pone.0181844. eCollection 2017.

24.

Allergens displayed on virus-like particles are highly immunogenic but fail to activate human mast cells.

Engeroff P, Caviezel F, Storni F, Thoms F, Vogel M, Bachmann MF.

Allergy. 2018 Feb;73(2):341-349. doi: 10.1111/all.13268. Epub 2017 Sep 12.

PMID:
28787769
25.

Nanoassembly routes stimulate conflicting antibody quantity and quality for transmission-blocking malaria vaccines.

Leneghan DB, Miura K, Taylor IJ, Li Y, Jin J, Brune KD, Bachmann MF, Howarth M, Long CA, Biswas S.

Sci Rep. 2017 Jun 19;7(1):3811. doi: 10.1038/s41598-017-03798-3.

26.

Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax.

Cabral-Miranda G, Heath MD, Mohsen MO, Gomes AC, Engeroff P, Flaxman A, Leoratti FMS, El-Turabi A, Reyes-Sandoval A, Skinner MA, Kramer MF, Bachmann MF.

Vaccines (Basel). 2017 May 2;5(2). pii: E10. doi: 10.3390/vaccines5020010.

27.

Adjusted Particle Size Eliminates the Need of Linkage of Antigen and Adjuvants for Appropriated T Cell Responses in Virus-Like Particle-Based Vaccines.

Gomes AC, Flace A, Saudan P, Zabel F, Cabral-Miranda G, Turabi AE, Manolova V, Bachmann MF.

Front Immunol. 2017 Mar 6;8:226. doi: 10.3389/fimmu.2017.00226. eCollection 2017.

28.

Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination.

Mohsen MO, Gomes AC, Cabral-Miranda G, Krueger CC, Leoratti FM, Stein JV, Bachmann MF.

J Control Release. 2017 Apr 10;251:92-100. doi: 10.1016/j.jconrel.2017.02.031. Epub 2017 Feb 28.

PMID:
28257987
29.

Harnessing Nanoparticles for Immunomodulation and Vaccines.

Gomes AC, Mohsen M, Bachmann MF.

Vaccines (Basel). 2017 Feb 14;5(1). pii: E6. doi: 10.3390/vaccines5010006. Review.

30.

Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine.

Alves E, Salman AM, Leoratti F, Lopez-Camacho C, Viveros-Sandoval ME, Lall A, El-Turabi A, Bachmann MF, Hill AV, Janse CJ, Khan SM, Reyes-Sandoval A.

Clin Vaccine Immunol. 2017 Apr 5;24(4). pii: e00501-16. doi: 10.1128/CVI.00501-16. Print 2017 Apr.

31.

Detecting circulating antibodies by controlled surface modification with specific target proteins: Application to malaria.

Cardoso AR, Cabral-Miranda G, Reyes-Sandoval A, Bachmann MF, Sales MGF.

Biosens Bioelectron. 2017 May 15;91:833-841. doi: 10.1016/j.bios.2017.01.031. Epub 2017 Jan 15.

PMID:
28157657
32.

Distinct T helper cell dependence of memory B-cell proliferation versus plasma cell differentiation.

Zabel F, Fettelschoss A, Vogel M, Johansen P, Kündig TM, Bachmann MF.

Immunology. 2017 Mar;150(3):329-342. doi: 10.1111/imm.12688. Epub 2017 Jan 5.

33.

The True Story and Advantages of RNA Phage Capsids as Nanotools.

Pumpens P, Renhofa R, Dishlers A, Kozlovska T, Ose V, Pushko P, Tars K, Grens E, Bachmann MF.

Intervirology. 2016;59(2):74-110. doi: 10.1159/000449503. Epub 2016 Nov 10. Review.

34.

Allergen-specific immunotherapy: is it vaccination against toxins after all?

Bachmann MF, Kündig TM.

Allergy. 2017 Jan;72(1):13-23. doi: 10.1111/all.12890. Epub 2016 Sep 28. Review.

PMID:
27558586
35.

Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization.

Brune KD, Leneghan DB, Brian IJ, Ishizuka AS, Bachmann MF, Draper SJ, Biswas S, Howarth M.

Sci Rep. 2016 Jan 19;6:19234. doi: 10.1038/srep19234.

36.

Development of an Interleukin-1β Vaccine in Patients with Type 2 Diabetes.

Cavelti-Weder C, Timper K, Seelig E, Keller C, Osranek M, Lässing U, Spohn G, Maurer P, Müller P, Jennings GT, Willers J, Saudan P, Donath MY, Bachmann MF.

Mol Ther. 2016 May;24(5):1003-12. doi: 10.1038/mt.2015.227. Epub 2015 Dec 21.

37.

Is The Allergen Really Needed in Allergy Immunotherapy?

Kündig TM, Klimek L, Schendzielorz P, Renner WA, Senti G, Bachmann MF.

Curr Treat Options Allergy. 2015;2(1):72-82. Review.

38.

Protective effect of a germline, IL-17-neutralizing antibody in murine models of autoimmune inflammatory disease.

Dallenbach K, Maurer P, Röhn T, Zabel F, Kopf M, Bachmann MF.

Eur J Immunol. 2015 Apr;45(4):1238-47. doi: 10.1002/eji.201445017. Epub 2015 Jan 23.

39.

Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs.

Klimek L, Bachmann MF, Senti G, Kündig TM.

Expert Rev Clin Immunol. 2014 Aug;10(8):1059-67. doi: 10.1586/1744666X.2014.924854. Epub 2014 Jun 5. Review.

PMID:
24898577
40.

Viral particles drive rapid differentiation of memory B cells into secondary plasma cells producing increased levels of antibodies.

Zabel F, Mohanan D, Bessa J, Link A, Fettelschoss A, Saudan P, Kündig TM, Bachmann MF.

J Immunol. 2014 Jun 15;192(12):5499-508. doi: 10.4049/jimmunol.1400065. Epub 2014 May 12.

41.

Vaccination against Alzheimer disease: an update on future strategies.

Fettelschoss A, Zabel F, Bachmann MF.

Hum Vaccin Immunother. 2014;10(4):847-51. Epub 2014 Feb 17. Review.

42.

Intralymphatic immunotherapy: time interval between injections is essential.

Kündig TM, Johansen P, Bachmann MF, Cardell LO, Senti G.

J Allergy Clin Immunol. 2014 Mar;133(3):930-1. doi: 10.1016/j.jaci.2013.11.036. Epub 2014 Jan 15. No abstract available.

PMID:
24439076
43.

Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes.

Spohn G, Schori C, Keller I, Sladko K, Sina C, Guler R, Schwarz K, Johansen P, Jennings GT, Bachmann MF.

Mol Ther Methods Clin Dev. 2014 Oct 22;1:14048. doi: 10.1038/mtm.2014.48. eCollection 2014.

44.

IgG-mediated down-regulation of IgE bound to mast cells: a potential novel mechanism of allergen-specific desensitization.

Uermösi C, Zabel F, Manolova V, Bauer M, Beerli RR, Senti G, Kündig TM, Saudan P, Bachmann MF.

Allergy. 2014 Mar;69(3):338-47. doi: 10.1111/all.12327. Epub 2013 Dec 19. Erratum in: Allergy. 2014 Aug;69(8):1118.

PMID:
24354793
45.

Bacterially produced recombinant influenza vaccines based on virus-like particles.

Jegerlehner A, Zabel F, Langer A, Dietmeier K, Jennings GT, Saudan P, Bachmann MF.

PLoS One. 2013 Nov 18;8(11):e78947. doi: 10.1371/journal.pone.0078947. eCollection 2013.

46.

Enhanced neutralizing antibody titers and Th1 polarization from a novel Escherichia coli derived pandemic influenza vaccine.

Skibinski DA, Hanson BJ, Lin Y, von Messling V, Jegerlehner A, Tee JB, Chye de H, Wong SK, Ng AA, Lee HY, Au B, Lee BT, Santoso L, Poidinger M, Fairhurst AM, Matter A, Bachmann MF, Saudan P, Connolly JE.

PLoS One. 2013 Oct 18;8(10):e76571. doi: 10.1371/journal.pone.0076571. eCollection 2013.

47.

Plasmodium vivax malaria vaccines: why are we where we are?

Reyes-Sandoval A, Bachmann MF.

Hum Vaccin Immunother. 2013 Dec;9(12):2558-65. doi: 10.4161/hv.26157. Epub 2013 Aug 26. Review.

48.

Virus-induced humoral immunity: on how B cell responses are initiated.

Zabel F, Kündig TM, Bachmann MF.

Curr Opin Virol. 2013 Jun;3(3):357-62. doi: 10.1016/j.coviro.2013.05.004. Epub 2013 Jun 1. Review.

PMID:
23731601
49.

Active immunotherapy for chronic diseases.

Bachmann MF, Whitehead P.

Vaccine. 2013 Apr 3;31(14):1777-84. doi: 10.1016/j.vaccine.2013.02.001. Epub 2013 Feb 14. Review.

PMID:
23415932
50.

The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma.

Beeh KM, Kanniess F, Wagner F, Schilder C, Naudts I, Hammann-Haenni A, Willers J, Stocker H, Mueller P, Bachmann MF, Renner WA.

J Allergy Clin Immunol. 2013 Mar;131(3):866-74. doi: 10.1016/j.jaci.2012.12.1561. Epub 2013 Feb 4.

PMID:
23384679

Supplemental Content

Loading ...
Support Center